Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbuhaler, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation powder for oral inhalation use. It provides bronchodilation to help manage airflow limitation in patients with asthma and chronic obstructive pulmonary disease (COPD). GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth muscle to improve airflow in obstructive lung diseases. - Asthma: improves symptom control and reduces the frequency of bronchospasm episodes. - Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases exacerbation risk. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways during physical activity.

Formoterol may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Tremor: mild shaking  - Headache  - Throat irritation  - Cough  - Nasal congestion  - Dry mouth

Serious or Rare Side Effects: - Paradoxical bronchospasm  - Cardiac arrhythmia  - Hypokalemia  - Severe allergic reaction (anaphylaxis) - Persistent tachycardia  - Upper‑airway inflammation  - Unexplained worsening of asthma control

When using Oxis Turbuhaler, patients and healthcare professionals should consider several safety measures. - Assess    :  Evaluate    "); -   ");   -   "  "  "  " "  " " " " " "  "  \